Bio News
MedPacto has applied to the U.S. Food and Drug Administration (FDA) for approval of an amendment to the phase 1/2 clinical trial protocol for vactosertib monotherapy in patients with relapsed, refractory or progressive osteosarcoma.
The amendment is intended to determine the optimal dose by comparing the efficacy and safety of the 200-mg and 300-mg doses.
The clinical trial will be conducted at UH Rainbow Babies & Children’s Hospital at Case Western Reserve University in the United States.
Biobook Team
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
